The present study aimed to evaluate the potential role of PIVKA-II in PC: we compared its serum concentration to other already established tumour markers (CA19-9, CEA and CA 242) measured in patients affected by PC and in patients with benign pancreatic diseases. This evidence concerns the gene CEACAM5 and pachyonychia congenita.